Rational multitargeted intervention of epileptogenesis in a mouse model of temporal lobe epilepsy:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
2019
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | X, 183 Seiten Illustrationen, Diagramme |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV046411167 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 200206s2019 a||| m||| 00||| eng d | ||
| 016 | 7 | |a 1201679451 |2 DE-101 | |
| 035 | |a (OCoLC)1138940781 | ||
| 035 | |a (DE-599)DNB1201679451 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-188 | ||
| 100 | 1 | |a Welzel, Lisa |e Verfasser |0 (DE-588)1204027609 |4 aut | |
| 245 | 1 | 0 | |a Rational multitargeted intervention of epileptogenesis in a mouse model of temporal lobe epilepsy |c by Lisa Welzel |
| 264 | 1 | |c 2019 | |
| 300 | |a X, 183 Seiten |b Illustrationen, Diagramme | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 7 | |a mice |2 cabt | |
| 650 | 7 | |a animal models |2 cabt | |
| 650 | 7 | |a epilepsy |2 cabt | |
| 650 | 7 | |a anticonvulsant properties |2 cabt | |
| 650 | 7 | |a drug combinations |2 cabt | |
| 650 | 7 | |a drug synergy |2 cabt | |
| 650 | 7 | |a drug interactions |2 cabt | |
| 655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
| 856 | 4 | 2 | |m B:DE-101 |q application/pdf |u https://d-nb.info/1201679451/04 |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=031823787&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031823787 | ||
Datensatz im Suchindex
| _version_ | 1804180950410592256 |
|---|---|
| adam_text | TABLE
OF
CONTENTS
1
ABSTRACT
...............................................................................................
1
2
ZUSAMMENFASSUNG
.............................................................................
3
3
GENERAL
INTRODUCTION
........................................................................
5
3.1
EPILEPSY
............................................................................................................
5
3.1.1
DEFINITION
AND
SIGNIFICANCE
.............................................................................................
5
3.1.2
TEMPORAL
LOBE
EPILEPSY
..................................................................................................
7
3.1.3
TREATMENT
OPTIONS
............................................................................................................
8
3.2
EPILEPTOGENESIS
AND
EPILEPSY
PREVENTION
......................................................
9
3.2.1
DEFINITION
AND
SIGNIFICANCE
.............................................................................................
9
3.2.2
NETWORK
PHARMACOLOGY
................................................................................................
12
3.3
ANIMAL
MODELS
IN
EPILEPSY
RESEARCH
............................................................
14
3.3.1
INTRAHIPPOCAMPAL
KAINATE
MOUSE
MODEL
......................................................................
16
3.3.2
PRECLINICAL
DRUG
DEVELOPMENT
IN
EPILEPSY
RESEARCH
....................................................
19
3.4
POTENTIALLY
ANTIEPILEPTOGENIC
DRUGS
AND
THEIR
MECHANISMS
OF
ACTION
.......
22
3.4.1
A-TOCOPHEROL
.................................................................................................................
23
3.4.2
ATORVASTATIN
...................................................................................................................24
3.4.3
CEFTRIAXONE
....................................................................................................................
25
3.4.4
CELECOXIB
.......................................................................................................................
26
3.4.5
DEFEROXAMINE
................................................................................................................
27
3.4.6
FINGOLIMOD
....................................................................................................................
28
3.4.7
GABAPENTIN
.....................................................................................................................
29
3.4.8
LEVETIRACETAM
................................................................................................................
30
3.4.9
MELATONIN
.......................................................................................................................
31
3.4.10
TOPIRAMATE
................................................................................................................
33
4
WORKING
HYPOTHESIS
AND
AIM
OF
STUDIES
........................................
35
5
NETWORK
PHARMACOLOGY
FOR
ANTIEPILEPTOGENESIS:
TOLERABILITY
AND
NEUROPROTECTIVE
EFFECTS
OF
NOVEL
MULTITARGETED
COMBINATION
TREATMENTS
IN
NONEPILEPTIC
VS.
POST-STATUS
EPILEPTICUS
MICE
.........37
5.1
ABSTRACT
..........................................................................................................
38
6
ANTIEPILEPTOGENIC
EFFICACY
OF
PROMISING
DRUG
COMBINATIONS
IN
THE
INTRAHIPPOCAMPAL
KAINATE
MOUSE
MODEL
................................ 39
6.1
INTRODUCTION
...................................................................................................
40
I
6.2
MATERIALS
AND
METHODS
..................................................................................
41
6.2.1
ANIMALS
.........................................................................................................................
41
6.2.2
INTRAHIPPOCAMPAL
KAINATE
MOUSE
MODEL
......................................................................
42
6.2.3
DRUG
TREATMENT
...............................................................................................................
45
6.2.4
VIDEO/EEG
MONITORING
.................................................................................................
48
6.2.5
HISTOLOGY
.......................................................................................................................
51
6.2.6
DRUGS
.............................................................................................................................
53
6.2.7
ANIMALS
EXCLUDED
FROM
ANALYSIS
.................................................................................
54
6.2.8
STATISTICS
.........................................................................................................................
55
6.3
RESULTS
............................................................................................................
56
6.3.1
TOLERABILITY
OF
DRUG
COMBINATIONS
...............................................................................
56
6.3.2
LEVETIRACETAM
+
GABAPENTIN
+
TOPIRAMATE
.................................................................
59
6.3.3
LEVETIRACETAM
+
A-TOCOPHEROL
....................................................................................
64
6.3.4
LEVETIRACETAM
+
DEFEROXAMINE
+
GABAPENTIN
+
FINGOLIMOD
.....................................
68
6.3.5
LEVETIRACETAM
+
ATORVASTATIN
+
CEFTRIAXONE
...............................................................
78
6.3.6
LEVETIRACETAM
+
ATORVASTATIN
+
CEFTRIAXONE
(REDUCED
DOSES)
....................................
82
6.3.7
POST
HOC
POWER
ANALYSIS
...............................................................................................
90
6.3.8
OVERALL
COMPARISON
OF
TESTED
DRUG
COMBINATIONS
.......................................................
93
6.4
DISCUSSION
....................................................................................................
103
6.5
ACKNOWLEDGEMENTS
.....................................................................................
110
6.6
REFERENCES
....................................................................................................
110
7
GENERAL
DISCUSSION
......................................................................
ILL
7.1
SELECTION
OF
DRUGS,
DRUG
DOSES,
AND
DOSE
INTERVALS
...................................
ILL
7.2
SOLUBILITY
EXPERIMENTS
................................................................................
114
7.3
MOUSE
STRAIN
.................................................................................................
115
7.4
INTRAHIPPOCAMPAL
KAINATE
MOUSE
MODEL
....................................................
117
7.5
TOLERABILITY
OF
DRUG
COMBINATIONS
(PHASE
I
AND
ILA)
.................................
119
7.5.1
PHASE
I:
TOLERABILITY
IN
NONEPILEPTIC
MICE
.................................................................
120
7.5.2
PHASE
ILA:
TOLERABILITY
IN
MICE
DURING
THE
LATENT
PHASE
(POST-SE)
...........................
121
7.6
ANTIEPILEPTOGENIC
EFFICACY
OF
DRUG
COMBINATIONS
(PHASE
LIB)
................
122
7.6.1
LEVETIRACETAM
+
GABAPENTIN
4-
TOPIRAMATE
.................................................................
124
7.6.2
LEVETIRACETAM
+
A-TOCOPHEROL
....................................................................................
126
7.6.3
LEVETIRACETAM
+
DEFEROXAMINE
+
GABAPENTIN
+
FINGOLIMOD
......................................
127
7.6.4
LEVETIRACETAM
+
ATORVASTATIN
+
CEFTRIAXONE
...............................................................
127
7.6.5
POST
HOC
POWER
ANALYSIS
.............................................................................................
128
II
7.7
CONCLUDING
REMARKS
..................................................................................
128
8
REFERENCES
......................................................................................
132
9
SUPPLEMENTAL
MATERIAL
..................................................................
176
9.1
HISTOLOGICAL
AND
IMMUNOHISTOLOGICAL
STAININGS
......................................
176
10
PUBLICATIONS
AND
CONFERENCE
CONTRIBUTIONS
..............................
179
10.1
PUBLICATIONS
...............................................................................................
179
10.2
POSTER
PRESENTATIONS
..................................................................................
179
10.3
ORAL
PRESENTATIONS
.....................................................................................
180
11
ACKNOWLEDGEMENTS
.....................................................................
182
HI
|
| any_adam_object | 1 |
| author | Welzel, Lisa |
| author_GND | (DE-588)1204027609 |
| author_facet | Welzel, Lisa |
| author_role | aut |
| author_sort | Welzel, Lisa |
| author_variant | l w lw |
| building | Verbundindex |
| bvnumber | BV046411167 |
| ctrlnum | (OCoLC)1138940781 (DE-599)DNB1201679451 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01427nam a2200373 c 4500</leader><controlfield tag="001">BV046411167</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">200206s2019 a||| m||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1201679451</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1138940781</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1201679451</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-188</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Welzel, Lisa</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1204027609</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Rational multitargeted intervention of epileptogenesis in a mouse model of temporal lobe epilepsy</subfield><subfield code="c">by Lisa Welzel</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">X, 183 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mice</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">animal models</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">epilepsy</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">anticonvulsant properties</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">drug combinations</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">drug synergy</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">drug interactions</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">B:DE-101</subfield><subfield code="q">application/pdf</subfield><subfield code="u">https://d-nb.info/1201679451/04</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=031823787&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031823787</subfield></datafield></record></collection> |
| genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
| genre_facet | Hochschulschrift |
| id | DE-604.BV046411167 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T08:43:54Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031823787 |
| oclc_num | 1138940781 |
| open_access_boolean | |
| owner | DE-188 |
| owner_facet | DE-188 |
| physical | X, 183 Seiten Illustrationen, Diagramme |
| publishDate | 2019 |
| publishDateSearch | 2019 |
| publishDateSort | 2019 |
| record_format | marc |
| spelling | Welzel, Lisa Verfasser (DE-588)1204027609 aut Rational multitargeted intervention of epileptogenesis in a mouse model of temporal lobe epilepsy by Lisa Welzel 2019 X, 183 Seiten Illustrationen, Diagramme txt rdacontent n rdamedia nc rdacarrier mice cabt animal models cabt epilepsy cabt anticonvulsant properties cabt drug combinations cabt drug synergy cabt drug interactions cabt (DE-588)4113937-9 Hochschulschrift gnd-content B:DE-101 application/pdf https://d-nb.info/1201679451/04 Inhaltsverzeichnis DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=031823787&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Welzel, Lisa Rational multitargeted intervention of epileptogenesis in a mouse model of temporal lobe epilepsy mice cabt animal models cabt epilepsy cabt anticonvulsant properties cabt drug combinations cabt drug synergy cabt drug interactions cabt |
| subject_GND | (DE-588)4113937-9 |
| title | Rational multitargeted intervention of epileptogenesis in a mouse model of temporal lobe epilepsy |
| title_auth | Rational multitargeted intervention of epileptogenesis in a mouse model of temporal lobe epilepsy |
| title_exact_search | Rational multitargeted intervention of epileptogenesis in a mouse model of temporal lobe epilepsy |
| title_full | Rational multitargeted intervention of epileptogenesis in a mouse model of temporal lobe epilepsy by Lisa Welzel |
| title_fullStr | Rational multitargeted intervention of epileptogenesis in a mouse model of temporal lobe epilepsy by Lisa Welzel |
| title_full_unstemmed | Rational multitargeted intervention of epileptogenesis in a mouse model of temporal lobe epilepsy by Lisa Welzel |
| title_short | Rational multitargeted intervention of epileptogenesis in a mouse model of temporal lobe epilepsy |
| title_sort | rational multitargeted intervention of epileptogenesis in a mouse model of temporal lobe epilepsy |
| topic | mice cabt animal models cabt epilepsy cabt anticonvulsant properties cabt drug combinations cabt drug synergy cabt drug interactions cabt |
| topic_facet | mice animal models epilepsy anticonvulsant properties drug combinations drug synergy drug interactions Hochschulschrift |
| url | https://d-nb.info/1201679451/04 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=031823787&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT welzellisa rationalmultitargetedinterventionofepileptogenesisinamousemodeloftemporallobeepilepsy |
Es ist kein Print-Exemplar vorhanden.
Inhaltsverzeichnis